<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01340001</url>
  </required_header>
  <id_info>
    <org_study_id>2011/049/HP</org_study_id>
    <secondary_id>2011-A00387-34</secondary_id>
    <nct_id>NCT01340001</nct_id>
  </id_info>
  <brief_title>Effects of Nucleus Basalis of Meynert Stimulation on Cognitive Disorders in Dementia With Lewy Bodies</brief_title>
  <acronym>DEMENSTIM</acronym>
  <official_title>Effects of Nucleus Basalis of Meynert Area Electrical Stimulation on Cognitive Behavioral Disorders in Dementia With Lewy Bodies : A Pilot Phase 1 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Deep brain stimulation has been developed as a substitute for the classical lesioning methods&#xD;
      previously used in stereotactic and functional neurosurgery. Recent, anecdotal cases reports&#xD;
      suggested that electrical stimulation of the cholinergic output of the Nucleus Basalis of&#xD;
      Meynert (NBM) may improve cognitive performances, especially the memory tasks.&#xD;
&#xD;
      The present study aims to assess the effect of bilateral electrical stimulation of the NBM on&#xD;
      the mnesic performance [assessed by the sum of the three free recalls of the Free and Cued&#xD;
      Selective Recall Reminding Test (FCSRT)] in patients diagnosed with probable, moderate,&#xD;
      Dementia with Lewy Bodies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 24, 2012</start_date>
  <completion_date type="Actual">December 22, 2017</completion_date>
  <primary_completion_date type="Actual">December 22, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>free recalls of the FCSRT</measure>
    <time_frame>between the assessments (Month 7) and (Month 10)</time_frame>
    <description>The primary endpoint of the study is the difference in the sum of the three free recalls of the FCSRT between the assessments (M7) and (M10), i.e. the comparison of the performances with and without NBM electrical stimulation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>performances on different tests</measure>
    <time_frame>different tests recorded at Month 7 and Month 10</time_frame>
    <description>Comparison will be made between the performances on different tests recorded at M7 and M10, to evaluate the effect of bilateral electrical stimulation of the NBM on cognitivo-behavioral disorders.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Dementia With Lewy Bodies</condition>
  <arm_group>
    <arm_group_label>Sham Electrical stimulation of the nucleus basalis of Meynert</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Deep brain stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Electrical stimulation of the nucleus basalis of Meynert</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deep brain stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Electrical stimulation of the nucleus basalis of Meynert</intervention_name>
    <description>Differents parameters will be assessed.</description>
    <arm_group_label>Electrical stimulation of the nucleus basalis of Meynert</arm_group_label>
    <arm_group_label>Sham Electrical stimulation of the nucleus basalis of Meynert</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of probable Lewy-body dementia according to the internationally accepted&#xD;
             consensus criteria (McKeith, 2005)&#xD;
&#xD;
          -  Outpatients, male or female, aged between 18 to 75 years&#xD;
&#xD;
          -  Moderate dementia defined by a mini-mental state examination (MMSE) score between 16&#xD;
             and 26&#xD;
&#xD;
          -  Stable dose of cholinesterase inhibitors (maximal dose tolerated) for a minimum of 1&#xD;
             months&#xD;
&#xD;
          -  Patients receiving antiparkinsonian treatment unmodified for 3 months, if treated&#xD;
&#xD;
          -  French as native language&#xD;
&#xD;
          -  Written informed consent of the patient&#xD;
&#xD;
          -  Written informed consent of the caregiver&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other causes of dementia (Alzheimer dementia, vascular dementia, dementia associated&#xD;
             with Parkinson's disease)&#xD;
&#xD;
          -  Other causes of extrapyramidal symptoms (Parkinson's disease)&#xD;
&#xD;
          -  Patients with a history of severe psychiatric disorders, such as psychosis. Earlier&#xD;
             episodes of depression and/or anxiety without hospitalization are not exclusion&#xD;
             criteria&#xD;
&#xD;
          -  Contraindications for MR imaging (claustrophobia, metallic foreign bodies, pacemakers,&#xD;
             etc)&#xD;
&#xD;
          -  MRI evidence of cerebral microbleeds&#xD;
&#xD;
          -  Surgical contraindications: especially, hemostatic disorders, severe cortical atrophy&#xD;
&#xD;
          -  Patients receiving treatments that may interfere with the cholinergic system:&#xD;
             anticholinergics, cholinomimetics.&#xD;
&#xD;
          -  Patients receiving neuroleptics&#xD;
&#xD;
          -  Patients with a history of alcohol or drug abuse&#xD;
&#xD;
          -  Pre-existing structural brain abnormalities (such as tumor, infarction, or&#xD;
             intracranial hematoma)&#xD;
&#xD;
          -  Previous neurosurgical intervention&#xD;
&#xD;
          -  Patients with a progressively fatal disease, or life expectancy £ one year&#xD;
&#xD;
          -  Asthma&#xD;
&#xD;
          -  Severe visual deficit of ophthalmic origin (such as glaucoma, age related macular&#xD;
             degeneration, cataract)&#xD;
&#xD;
          -  Fertile women not using adequate contraceptive methods&#xD;
&#xD;
          -  Women who are pregnant or breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier GODEFROY, Md, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Amiens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luc DEFEBVRE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Lille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>HOUETO Jean-Luc, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Poitiers</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre Krystkowiak, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Amiens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vincent Delasayette, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Caen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maltête David</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>April 5, 2011</study_first_submitted>
  <study_first_submitted_qc>April 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2011</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dementia with Lewy bodies</keyword>
  <keyword>Nucleus basalis of Meynert</keyword>
  <keyword>Deep brain stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Lewy Body Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

